Avanos Medical, Inc.·Healthcare
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

AVNS, BKR and CAG have been added to the Zacks Rank #5 (Strong Sell) List on May 15th, 2026.

Explore Avanos Medical's (AVNS) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Avanos Medical tops Q1 revenue estimates on strong SNS growth, but margin pressure and PM&R weakness weigh on earnings and profitability.

BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.

Avanos Medical (AVNS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.26 per share a year ago.

Delivered double-digit organic growth led by Specialty Nutrition Systems segment Generated $0.11 of diluted earnings per share and $0.22 of adjusted diluted earnings per share On April 14, 2026, announced the execution of a definitive agreement to be acquired by certain affiliates of American Industrial Partners ("AIP") in an all-cash offer at an enterprise value of $1.272 billion ALPHARETTA, Ga., May 5, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2026 financial results.